The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.

ABSTRACT:

Importance

There is a significant need to find biomarkers of response to radiotherapy and cetuximab in locally advanced head and neck squamous cell carcinoma (HNSCC) and biomarkers that predict altered immunity, thereby enabling personalized treatment.

Objectives

To examine whether the Kirsten rat sarcoma viral oncogene homolog (KRAS)-variant, a germline mutation in a microRNA-binding site in KRAS, is a predictive biomarker of cetuximab response and altered immunity in the setting of radiotherapy and cisplatin treatment and to evaluate the interaction of the KRAS-variant with p16 status and blood-based transforming growth factor β1 (TGF-β1).

Design, setting, and participants

A total of 891 patients with advanced HNSCC from a phase 3 trial of cisplatin plus radiotherap

SUBMITTER: Weidhaas JB 

PROVIDER: S-EPMC5470422 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature